SCHEMBL2660583

SCHEMBL2660583

FC(F)(F)c1ccc2[nH]nc(Nc3nccs3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 4/20 0.54
FADS1 O60427 1/20 0.54
TRPA1 O75762 3/20 0.48
KCNQ3 O43525 1/20 0.47
KCNQ2 O43526 1/20 0.47
KCNQ1 P51787 1/20 0.47
SCN5A Q14524 1/20 0.47
MAP2K4 P45985 3/20 0.46
MAPK1 P28482 3/20 0.46
MAPKAPK3 Q16644 2/20 0.46
MAPK6 Q16659 2/20 0.46
MAPKAPK2 P49137 1/20 0.46
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SCN9A Q15858 5/20 0.40
KIF11 P52732 1/20 0.39
SCN3A Q9NY46 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660635 0.81 GRM4 (0.58) GRM4FADS1MAPK1
SCHEMBL2660111 0.81 GRM4 (0.58) GRM4FADS1MAP2K4MAPK1MAPKAPK3
SCHEMBL2660645 0.81 GRM4 (0.58) GRM4FADS1TRPA1MAPK1
SCHEMBL2667982 0.81 GRM4 (0.58) GRM4FADS1MAPK1ALDH1A1TDP1
SCHEMBL2668091 0.79 GRM4 (0.55) GRM4FADS1MAPK1
SCHEMBL2656814 0.78 FADS1 (0.55) GRM4FADS1TRPA1KCNQ3KCNQ2
SCHEMBL9072655 0.78 GRM4 (0.55) GRM4FADS1MAPK1
SCHEMBL2654720 0.78 GRM4 (0.54) GRM4FADS1MAPK1
SCHEMBL2659835 0.78 GRM4 (0.54) GRM4FADS1MAPK1
SCHEMBL2662181 0.78 GRM4 (0.54) GRM4MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP claimed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US claimed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO claimed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 US disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244169-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GRM4 1511/4885FADS1 1868/4885TRPA1 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.